These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 8689509)

  • 21. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model.
    Tan J; Newton CA; Djeu JY; Gutsch DE; Chang AE; Yang NS; Klein TW; Hua Y
    Cancer Res; 1996 Aug; 56(15):3399-403. PubMed ID: 8758901
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy.
    Neal ZC; Yang JC; Rakhmilevich AL; Buhtoiarov IN; Lum HE; Imboden M; Hank JA; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Clin Cancer Res; 2004 Jul; 10(14):4839-47. PubMed ID: 15269160
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant melanoma and renal cell carcinoma: immunological and haematological effects of recombinant human interleukin-2.
    Hayat K; Rodgers S; Bruce L; Rees RC; Chapman K; Reeder S; Dorreen MS; Sheridan E; Sreenivasan T; Hancock BW
    Eur J Cancer; 1991; 27(8):1009-14. PubMed ID: 1832884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor protection from the murine T-cell leukemia/lymphoma EL4 by the continuous subcutaneous coadministration of recombinant macrophage-colony stimulating factor and interleukin-2.
    Vallera DA; Taylor PA; Aukerman SL; Blazar BR
    Cancer Res; 1993 Sep; 53(18):4273-80. PubMed ID: 8364923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Augmentation of cell-mediated cytotoxicity against renal carcinoma cells by recombinant interleukin 2.
    Marumo K; Ueno M; Muraki J; Baba S; Tazaki H
    Urology; 1987 Oct; 30(4):327-32. PubMed ID: 3116737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma.
    Younes E; Haas GP; Dezso B; Ali E; Maughan RL; Kukuruga MA; Montecillo E; Pontes JE; Hillman GG
    Cell Immunol; 1995 Oct; 165(2):243-51. PubMed ID: 7553889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Systemic treatment with interleukin-4 induces regression of pulmonary metastases in a murine renal cell carcinoma model.
    Hillman GG; Younes E; Visscher D; Ali E; Lam JS; Montecillo E; Pontes JE; Haas GP; Puri RK
    Cell Immunol; 1995 Feb; 160(2):257-63. PubMed ID: 7720087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
    Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study.
    Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ
    J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with adriamycin and interleukin 2 augments immunity against murine renal cell carcinoma.
    Gautam SC; Chikkala NF; Ganapathi R; Hamilton TA
    Cancer Res; 1991 Nov; 51(22):6133-7. PubMed ID: 1682042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity.
    Mendiratta SK; Quezada A; Matar M; Wang J; Hebel HL; Long S; Nordstrom JL; Pericle F
    Gene Ther; 1999 May; 6(5):833-9. PubMed ID: 10505108
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunostimulatory therapy with anti-CD3 monoclonal antibodies and recombinant interleukin-2: heightened in vivo expression of mRNA encoding cytotoxic attack molecules and immunoregulatory cytokines and regression of murine renal cell carcinoma.
    Asano T; Khanna A; Lagman M; Li B; Suthanthiran M
    J Urol; 1997 Jun; 157(6):2396-401. PubMed ID: 9146677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ReGel polymer-based delivery of interleukin-2 as a cancer treatment.
    Samlowski WE; McGregor JR; Jurek M; Baudys M; Zentner GM; Fowers KD
    J Immunother; 2006; 29(5):524-35. PubMed ID: 16971808
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination treatment with irritant and recombinant interleukin 2 in the peritoneal cavity for evoking effective anti-tumor activity: generation of lymphokine-activated killer cells and tumor-specific killer cells.
    Uchida H; Taniguchi K; Nomoto K
    Jpn J Cancer Res; 1990 Apr; 81(4):416-24. PubMed ID: 2114394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interleukin-6 induces drug resistance in renal cell carcinoma.
    Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
    Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma.
    Lawson KA; Mostafa AA; Shi ZQ; Spurrell J; Chen W; Kawakami J; Gratton K; Thakur S; Morris DG
    Clin Cancer Res; 2016 Dec; 22(23):5839-5850. PubMed ID: 27220962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rejection of mouse renal cell carcinoma elicited by local secretion of interleukin-2.
    Hara I; Hotta H; Sato N; Eto H; Arakawa S; Kamidono S
    Jpn J Cancer Res; 1996 Jul; 87(7):724-9. PubMed ID: 8698622
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.